Thursday, November 27, 2014

Avivagen’s OxC-beta in peer-reviewed journal

Avivagen’s OxC-beta in peer-reviewed journal

November 26, 2014 by · Leave a Comment 

Tweet The American Journal of Veterinary Research has published results of a study of the utility and mechanisms of Avivagen’s (TSXV:VIV) OxC‐beta, a fundamentally new natural alternative to the use of antibiotics in livestock feeds. Independent scientists from the University of Calgary and the University of Alberta conducted the study. Entitled, “Anti‐inflammatory effects of retinoids […]

Cynapsus to uplist to TSX on Nov. 28

Cynapsus to uplist to TSX on Nov. 28

November 25, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX:CTH) will begin trading on the Toronto Stock Exchange at the opening this Friday, Nov. 28. The shares will continue to trade under the symbol CTH. Trading on the TSX Venture Exchange will end on Friday. The change does not affect trading on the OTCQX International in the U.S. “Uplisting the […]

Amarantus posts positive preclinical data for retinitis pigmentosa

Amarantus posts positive preclinical data for retinitis pigmentosa

November 25, 2014 by · Leave a Comment 

Tweet Amarantus BioScience Holdings (OTCQB:AMBS) has announced positive effects of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the protection from vision loss in an animal model of retinitis pigmentosa (RP). A single intravitreal administration of MANF after the onset of retinal degeneration on day 31 resulted in a statistically significant protective effect on visual acuity on day […]

Transition reports positive tQT study for ELND005

Transition reports positive tQT study for ELND005

November 24, 2014 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has presented positive results at the Clinical Trials in Alzheimer’s Disease conference from a thorough QT (tQT) study in which no QT effects were observed at supra-therapeutic single doses of its neuropsychiatric drug candidate, ELND005. The QT interval represents the amount of time the heart’s electrical system takes to repolarize, […]

Analysts start Sientra at outperform

Analysts start Sientra at outperform

November 24, 2014 by · Leave a Comment 

Tweet Leerink Partners and William Blair have initiated coverage of Sientra (NASDAQ:SIEN) at “outperform” with Stifel opting for a “buy” recommendation. Sientra is a medical aesthetics company focused on selling differentiated, highly cohesive silicone implants used in breast augmentation and reconstruction procedures. Analyst Richard Newitter at Leerink set a $22 price target on the stock, […]

Avivagen posts positive preliminary data for OxC-beta

Avivagen posts positive preliminary data for OxC-beta

November 24, 2014 by · Leave a Comment 

Tweet Avivagen (TSX-V:VIV) has released positive preliminary results of independently conducted studies in Vietnam and Korea of the livestock utility of OxC-beta, a fundamentally new natural alternative to the use of antibiotics in livestock feeds. In swine, Avivagen believes the results of the 500-pig study are indicative of strong commercial utility. The inclusion of OxC-beta […]

Cipher to begin trading on NASDAQ on Monday

Cipher to begin trading on NASDAQ on Monday

November 21, 2014 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has been approved for listing and trading on the NASDAQ Global Market, effective at the open on Monday, under the ticker symbol CPHR. The common shares will continue to be listed on the Toronto Stock Exchange, however, the company’s ticker symbol will change to CPH also on Monday. “Listing on […]

Tandem Diabetes in data partnership with Tidepool

Tandem Diabetes in data partnership with Tidepool

November 21, 2014 by · Leave a Comment 

Tweet Tandem Diabetes Care (NASDAQ:TNDM) has entered into a partnership with Tidepool, a non-profit dedicated to improving diabetes therapy management by offering an open source software platform that increases diabetes data accessibility. The accord will enable users of the Tidepool Platform, which is currently under development, to download and access data from Tandem’s t:slim Insulin […]

Amarantus completes enrollment in expanded LP-002 study

Amarantus completes enrollment in expanded LP-002 study

November 20, 2014 by · Leave a Comment 

Tweet Amarantus Bioscience Holdings (OTCQB:AMBS) has completed enrollment in the expanded LP-002 study of the Lymphocyte Proliferation (LymPro Test) blood diagnostic for Alzheimer’s disease (AD). The test assesses LymPro’s predictive value in mild, moderate and severe AD vs. healthy controls. Amarantus expects to announce the full results of its in-depth analysis of the full mild-to-severe […]

Transition posts encouraging study results in Down syndrome

Transition posts encouraging study results in Down syndrome

November 20, 2014 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has announced encouraging results of a clinical study of neuropsychiatric drug candidate, ELND005, in young adults with Down syndrome. Transition’s wholly owned subsidiary, Transition Therapeutics Ireland (TTIL), completed this first study in Down syndrome subjects without dementia to allow optimal dose selection for future larger studies. The study enrolled 23 […]

Next Page »

Email Newsletters with Constant Contact
Google+